Bioasis Technologies

Bioasis Technologies Intangible Assets

The Intangible Assets of Bioasis Technologies (BIOAF) as of Oct 24, 2026 is 159,000.00 CAD. In the previous year, Intangible Assets was 212,800.00 CAD — a change of -25.28% (lower).

Intangible Assets

159,000.00CAD

YoY

-25.28%

Last updated:

Intangible Assets of Bioasis Technologies is 2022 159,000.00 CAD. Intangible Assets of Bioasis Technologies was 2021 212,800.00 CAD. It decreases by -25.28% lower compared to the previous year.

The Bioasis Technologies Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2015
470,000.00 CAD
Jan 1, 2016
425,200.00 CAD
Jan 1, 2017
376,200.00 CAD
Jan 1, 2018
386,600.00 CAD
Jan 1, 2019
327,800.00 CAD
Jan 1, 2020
269,100.00 CAD
Jan 1, 2021
212,800.00 CAD
Jan 1, 2022
159,000.00 CAD
The Bioasis Technologies Intangible Assets history
YEARIntangible AssetsYoY
159,000.00CAD-25.28%
212,800.00CAD-20.92%
269,100.00CAD-17.91%
327,800.00CAD-15.21%
386,600.00CAD+2.76%
376,200.00CAD-11.52%
425,200.00CAD-9.53%
470,000.00CAD-9.62%
520,000.00CAD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bioasis Technologies Stock analysis

What does Bioasis Technologies do? biOasis Technologies, Inc. generates revenue by developing therapeutics using its proprietary xB3 platform, which is designed to deliver treatments across the blood brain barrier for central nervous system disorders. The company focuses on areas of high unmet medical need, specifically targeting brain cancers and neurodegenerative diseases. This technology leverages a human transport protein found circulating at low levels in the blood to shuttle molecules to their targets within the brain via receptor-mediated transcytosis. The firm markets its in-house development programs aimed at creating both symptomatic and disease-modifying treatments for brain-related diseases and disorders. By utilizing the xB3 platform, biOasis Technologies, Inc. addresses specific therapeutic challenges in the central nervous system, offering solutions for conditions that currently lack adequate medical interventions. The business model relies on the efficacy of this delivery system to reach targets within the brain, serving the needs of patients suffering from these severe neurological conditions. Bioasis Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bioasis Technologies stock

Intangible Assets of Bioasis Technologies is 159,000.00 CAD in 2022.

Intangible Assets of Bioasis Technologies changed from 212,800.00 CAD to 159,000.00 CAD, representing a -25.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Bioasis Technologies since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's CAD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Bioasis Technologies historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Bioasis Technologies

All Key Metrics — Bioasis Technologies